Table 1. Demographics (n = 130).
| Depression status | |||||||
|---|---|---|---|---|---|---|---|
| No (n = 111) | Yes (N = 19) | Total | |||||
| N | % | N | % | N | % | p-value | |
| Age, years | 0.14 | ||||||
| Mean (SD) | 56.8 (9.4) | 53.3 (10.2) | 56.3 (9.6) | ||||
| Min - Max | 30.7 - 78.5 | 28.4 - 69.1 | 28.4 - 79.5 | ||||
| Sex | 0.32 | ||||||
| Male | 94 | 84.7 | 14 | 73.7 | 108 | 83.1 | |
| Female | 17 | 15.3 | 5 | 26.3 | 22 | 16.9 | |
| Recurrence or new primary cancer during follow-up | 0.067 | ||||||
| None | 91 | 82.0 | 12 | 63.2 | 103 | 79.2 | |
| Recurred or progressed | 10 | 9.0 | 5 | 26.3 | 15 | 11.5 | |
| New Primary | 10 | 9.0 | 2 | 10.5 | 12 | 9.2 | |
| Death during follow-up | 0.14 | ||||||
| No | 98 | 88.3 | 14 | 73.7 | 112 | 86.2 | |
| Yes | 13 | 11.7 | 5 | 26.3 | 18 | 13.8 | |
| AJCC tumor stage | 0.36 | ||||||
| I-II | 10 | 9.1 | 0 | 0.0 | 10 | 7.8 | |
| III-IV | 100 | 90.9 | 19 | 100.0 | 119 | 92.2 | |
| Tumor size/nodal involvement | 0.93 | ||||||
| T < T4 and N < N3/N2c | 74 | 66.7 | 14 | 73.7 | 88 | 67.7 | |
| Any N3/N2c except T4 | 18 | 16.2 | 2 | 10.5 | 20 | 15.4 | |
| Any T4 | 19 | 17.1 | 3 | 15.8 | 22 | 16.9 | |
| Neoadjuvant chemotherapy | 0.80 | ||||||
| Did not Receive | 70 | 63.1 | 13 | 68.4 | 83 | 63.8 | |
| Received | 41 | 36.9 | 6 | 31.6 | 47 | 36.2 | |
| Concurrent chemotherapy | 0.80 | ||||||
| Did not Receive | 68 | 61.3 | 11 | 57.9 | 79 | 60.8 | |
| Received | 43 | 38.7 | 8 | 42.1 | 51 | 39.2 | |
| Prior history of cancer at baseline | >0.99 | ||||||
| No | 105 | 94.6 | 18 | 94.7 | 123 | 94.6 | |
| Yes | 6 | 5.4 | 1 | 5.3 | 7 | 5.4 | |
| Smoking history at baseline | 0.39 | ||||||
| Never | 45 | 40.5 | 6 | 31.6 | 51 | 39.2 | |
| Former | 43 | 38.7 | 8 | 42.1 | 51 | 39.2 | |
| Recent | 8 | 7.2 | 0 | 0.0 | 8 | 6.2 | |
| Current | 15 | 13.5 | 5 | 26.3 | 20 | 15.4 | |
| History of stroke at baseline | 0.47 | ||||||
| No | 108 | 97.3 | 18 | 94.7 | 126 | 96.9 | |
| Yes | 3 | 2.7 | 1 | 5.3 | 4 | 3.1 | |
| Excessive alcohol use | 0.47 | ||||||
| No | 108 | 97.3 | 18 | 94.7 | 126 | 96.9 | |
| Yes | 3 | 2.7 | 1 | 5.3 | 4 | 3.1 | |
| Comorbid hypertension at baseline | 0.31 | ||||||
| No | 67 | 61.5 | 9 | 47.4 | 76 | 59.4 | |
| Yes | 42 | 38.5 | 10 | 52.6 | 52 | 40.6 | |
| Comorbid diabetes at baseline | >0.99 | ||||||
| No | 95 | 88.8 | 17 | 89.5 | 112 | 88.9 | |
| Yes | 12 | 11.2 | 2 | 10.5 | 14 | 11.1 | |
| Comorbid hyperlipidemia at baseline | 0.27 | ||||||
| No | 74 | 69.2 | 15 | 83.3 | 89 | 71.2 | |
| Yes | 33 | 30.8 | 3 | 16.7 | 36 | 28.8 | |
| Prior history of myocardial infarction at baseline | 0.59 | ||||||
| No | 103 | 94.5 | 19 | 100.0 | 122 | 95.3 | |
| Yes | 6 | 5.5 | 0 | 0.0 | 6 | 4.7 | |
| Comorbid coronary artery disease at baseline | 0.30 | ||||||
| No | 90 | 83.3 | 18 | 94.7 | 108 | 85.0 | |
| Yes | 18 | 16.7 | 1 | 5.3 | 19 | 15.0 | |
| Comorbid tachycardia at baseline | >0.99 | ||||||
| No | 103 | 95.4 | 18 | 94.7 | 121 | 95.3 | |
| Yes | 5 | 4.6 | 1 | 5.3 | 6 | 4.7 | |
| Number of comorbidities at baseline | 0.82 | ||||||
| 0 | 39 | 36.4 | 8 | 44.4 | 47 | 37.6 | |
| 1-3 | 63 | 58.9 | 10 | 55.6 | 73 | 58.4 | |
| >=4 | 5 | 4.7 | 0 | 0.0 | 5 | 4.0 | |
HR, hazard ratio; UB, upper bound; LB, lower bound. Boldface indicates statistical significance.